Effect of isoflavone on plasma nitrite/nitrate, homocysteine, and lipid levels in Turkish women in the early postmenopausal period: A randomized controlled trial

Turkish Journal of Medical Sciences

Volumn 39, Issue 3, 2009, Pages 367-375

  Öztürk Turhan, Nilgün ^a   Iltemir Duvan, Candan ^a   Bolkan, Fatma ^a   Onaran, Yüksel ^a  

^a FATIH UNIVERSITY   (Turkey)

Author keywords

Homocysteine; Isoflavone; Lipid; Menopause; Nitrite nitrate

Indexed keywords

CARDIO-VASCULAR DISEASE; CARDIOVASCULAR RISK; HIGH-DENSITY LIPOPROTEINS; HOMOCYSTEINE; ISOFLAVONE; ISOFLAVONES; LIPID LEVELS; LOW DENSITY LIPOPROTEINS; MENOPAUSE; NITRITE/NITRATE; PHYTOESTROGENS; RANDOMIZED CLINICAL TRIALS; RANDOMIZED CONTROLLED TRIAL; TRIGLYCERIDE LEVELS; TURKISHS;

BODY FLUIDS; LIPIDS; PLASMAS; PROTEINS;

PLASMA DIAGNOSTICS;

HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; ISOFLAVONE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NITRATE; NITRITE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC);

EID: 67649573994     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0803-39     Document Type: Article

References (31)

1. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149: 2445-8.
2. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-203.
3. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996 Aug 15; 335(7): 453-61.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al ; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
6. Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis. 1995 Sep-Oct;38(2):87-104. Review.
7. Sobey CG, Weiler JM, Boujaoude M, Woodman OL. Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol. J Pharmacol Exp Ther 2004; 310: 135-40.
8. Squadrito F, Altavilla D, Squadrito G, Saitta A, Cucinotta D, Minutoli L et al. Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc Res 2000; 45: 454-62.
9. Jenkins DJ, Kendall CW, Jackson CJ, Connelly PW, Parker T, Faulkner D et al. Effects of high- and low-isoflavone soyfoods on blood lipids, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am J Clin Nutr 2002; 76: 365-72.
10. Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000; 85: 1297-301.
11. Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 2006; 53: 252-9.
12. Reimann M, Dierkes J, Carlsohn A, Talbot D, Ferrari M, Hallund J et al. Consumption of soy isoflavones does not affect plasma total homocysteine or asymmetric dimethylarginine concentrations in healthy postmenopausal women J Nutr 2006; 136: 100-5.
13. D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and Creactive protein level in postmenopausal women. Acta Obstet Gynecol Scand 2005; 84: 474-7.
14. Hanson LN, Engelman HM, Alekel DL, Schalinske KL, Kohut ML, Reddy MB. Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am J Clin Nutr 2006; 84: 774-80.
15. Anderson JW, Johnstone BM, Cook-Newell ME. Metaanalysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995; 333: 276-82.
16. Blum A, Lang N, Vigder F, Israeli P, Gumanovsky M, Lupovitz S et al. Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin Invest Med 2003; 26: 20-6.
17. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein, daidzein, and their beta-glycozide conjugates-antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 1993; 41: 1961-1967.
18. Squadrito F, Altavilla D, Crisafulli A, Saitta A, Cucinotta D, Morabito N et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 2003; 114: 470-6.
19. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ.The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation. 2001; 103(2): 258-62.
20. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F et al. The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis. 2002 Aug;163(2):339-47.
21. Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001; 24: 228-33.
22. Baum JA, Teng H, Erdman JW Jr, Weigel RM, Klein BP, Persky VW et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 1998; 68: 545-51.
23. Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 2004; 134: 2395-400.
24. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA. 2004; 292: 65-74
25. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol. 2002; 22: 1852-8.
26. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause. 2006 Sep-Oct; 13(5): 831-9.
27. Howes LG, Howes JB, Knight DC. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas. 2006 Oct 20; 55(3): 203-11. Epub 2006 May 3.
28. Hall WL, Vafeiadou K, Hallund J, Bugel S, Koebnick C, Reimann M et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr. 2005 Dec; 82(6): 1260-8; quiz 1365-6.
29. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet. 2005 Aug; 90(2): 128-33.
30. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000; 283: 1845-52.
31. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002 Dec; 132(12): 3577-84. Review.